All In Biotech

Free tool

FAERS Monitor: Betoptic S

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 019845 or its brand name (Betoptic S, Betaxolol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

521

Serious

400

77% of reports

Hospitalization

242

Death reported

44

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fall67
  • dyspnoea61
  • drug ineffective50
  • pain39
  • dizziness38
  • asthma35
  • eye irritation35
  • fatigue34
  • nausea33
  • haemorrhage32
  • headache31
  • hypersensitivity31
  • cardiac failure congestive30
  • limb injury30
  • wound30

Reports by year received

View as table
YearReports
20046
200511
20066
200710
20088
200911
201011
201113
201213
201310
20149
201514
201619
201737
201848
201964
202031
202124
202243
202331
202455
202526
202621

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,638 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
limb injurySignal3044.631.51,237
woundSignal3043.430.61,200
eye irritationSignal3524.617.8769
cardiac failure congestiveSignal3015.110.7382
asthmaSignal3512.59.1361
haemorrhageSignal3212.48.8324
fallSignal678.16.5418
hypersensitivitySignal316.74.8147
dyspnoeaSignal614.43.4158
dizzinessSignal383.12.352
painSignal392.61.937
headache312.01.415
fatigue341.81.311
nausea331.71.29
drug ineffective501.51.29

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.